Core Viewpoint - During the "14th Five-Year Plan" period, Tibet Pharmaceutical has established itself as a benchmark enterprise in the Tibetan medicine industry, focusing on innovation and responsibility while achieving significant results in the modernization and high-quality development of ethnic medicine [1][2] Group 1: Business Development - Tibet Pharmaceutical has built an industrial layout covering Tibet, Sichuan, Shanghai, Hong Kong, and overseas, with multiple subsidiaries and a full-chain management platform [1] - The company’s core products focus on cardiovascular treatments, forming an industrial pattern that integrates biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs [1] - In 2024, Tibet Pharmaceutical achieved a revenue of 2.807 billion yuan, with a compound annual growth rate of 20% over the past five years; net profit attributable to shareholders was 1.051 billion yuan, a year-on-year increase of 31.26% [1] Group 2: Product Innovation - Tibet Pharmaceutical has achieved several industry firsts, including the self-developed "New Active Substance" (recombinant human brain natriuretic peptide injection), which is the first gene-engineered new drug for acute heart failure in China [1] - The exclusive Tibetan medicine "Nodikon Capsule" has been included in the national essential drug list and medical insurance directory, marking a significant product in the modernization of Tibetan medicine [1] - The acquisition of "Imdur" (isosorbide mononitrate sustained-release tablets) from AstraZeneca for $190 million enhances the company's portfolio of cardiovascular drugs [1] Group 3: Future Plans and Social Responsibility - In 2025, Tibet Pharmaceutical plans to invest $60 million in Ruizheng Gene to enter the gene editing sector, with its product ART001 recognized as an orphan drug by the FDA [2] - The company has invested 300 million yuan in Morningstar Pharmaceuticals to secure exclusive commercial sales rights for the lung cancer drug "Zolmitriptan" in mainland China, preparing for long-term growth [2] - Tibet Pharmaceutical has integrated social responsibility into its operations, contributing a total tax amount of 2.899 billion yuan, with 2.608 billion yuan paid in Tibet, and donating over 70 million yuan in medicines and materials [2] - Looking ahead to the "15th Five-Year Plan," Tibet Pharmaceutical aims to pursue growth through both internal development and external expansion, while continuing to contribute unique value to the pharmaceutical industry [2]

Core Viewpoint - The announcement by Tibet Pharmaceutical indicates that its subsidiary, Chengdu Nodi Kang Biopharmaceutical Co., Ltd., has its product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), included in the National Medical Insurance Directory for 2025 and adjusted to the regular directory [1] Group 1 - The product will continue to be covered by the national medical insurance, which is a significant advantage for the company [1] - The adjustment to the regular directory may enhance the product's market accessibility and potential sales [1]

Core Insights - Tibet Pharmaceutical has evolved from its establishment in 1999 to a modern pharmaceutical company integrating R&D, production, and sales, contributing significantly to the modernization of ethnic medicine and rural revitalization [1][2] - The company reported a revenue of 16.51 billion yuan and a net profit of 5.43 billion yuan for the first half of 2025, with a total revenue of 28.07 billion yuan and a net profit of 10.51 billion yuan in 2024, marking a year-on-year growth of 31.26% [1][2] - Tibet Pharmaceutical is recognized as a pioneer in the modernization of Tibetan medicine, with a focus on cardiovascular treatments and a global marketing network spanning over 40 countries [2] Company Development - Since its inception, Tibet Pharmaceutical has established a comprehensive management platform covering R&D, production, and marketing, with nine subsidiaries and a focus on modern Tibetan medicine, biopharmaceuticals, and innovative chemical drugs [2] - The company has achieved several industry firsts, including the development of "New Active Substance," the first gene-engineered drug for acute heart failure in China, and the inclusion of its unique Tibetan medicine "Nodikon Capsule" in national essential drug and medical insurance directories [2] Social Responsibility - Tibet Pharmaceutical has contributed significantly to local development, with a total tax contribution of 28.99 billion yuan since its listing, of which 26.08 billion yuan was paid in Tibet, accounting for 89.96% of the total [2] - The company actively supports rural revitalization through initiatives that combine industry, livelihood, and culture, including the artificial cultivation of Tibetan medicinal materials to enhance local farmers' income while protecting the fragile ecosystem [3] - Employment support initiatives include partnerships with educational institutions and training programs for Tibetan students, fostering local talent and promoting community development [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 *僅供識別 1 自願性及業務進展公告 創新藥心肌肌球蛋白抑制劑CMS-D003獲藥物臨床試驗批准通知書 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本集團」） 欣然宣佈，本集團自主研發的創新藥CMS-D003膠囊（「CMS-D003」）於二零二五年 三月十一日獲得中國國家藥品監督管理局（「NMPA」）簽發的藥物臨床試驗批准通知 書，於三月十二日收到藥物臨床試驗批准通知書。NMPA同意本集團在中國健康以及症 狀性梗阻性肥厚型心肌病（oHCM）成人受試者中開展評價CMS-D003安全性、耐受性 及藥代動力學和藥效學特徵的臨床試驗。 CMS-D003 CMS-D003是一種小分子心肌肌球蛋白抑制劑，是靶向治療肥厚型心肌病的藥物。通過 靶向抑制心肌肌球蛋白三磷酸腺苷（ATP）酶，抑制肌球蛋白-肌動蛋白相互作用，減少 肌絲滑動，抑制心肌的過度收縮，改善心 ...